CompletedPhase 3NCT04463056
Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH
Studying Paroxysmal nocturnal hemoglobinuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AO GENERIUM
- Principal Investigator
- Oksana A. Markova, MDAO GENERIUM
- Intervention
- Elizaria®(biological)
- Enrollment
- 32 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2017 – 2018
Study locations (4)
- Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia), Moscow, Russia
- Moscow State Budget Funded Healthcare Institution S. P. Botkin City Clinical Hospital, Moscow Department of Healthcare, Moscow, Russia
- State Budget Funded Institution of Higher Education Academician I. P. Pavlov Saint-Petersburg State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
- State Budgetary Educational Institution of Higher Professional Education Samara State Medical University, Ministry of Health of the Russian Federation., Samara, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04463056 on ClinicalTrials.govOther trials for Paroxysmal nocturnal hemoglobinuria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07154745A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRegeneron Pharmaceuticals
- RECRUITINGNCT07457151Danicopan PMS in KoreaAstraZeneca
- RECRUITINGPHASE1NCT07462780A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsShenzhen Kangzhe Biotechnology Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07470762Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07187401A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07229235REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT06934967Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsNovartis Pharmaceuticals